Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has shown promising financial recovery with its first half-year revenue growth since 2021, despite overall annual revenue decline due to supply constraints. The company reported a 36% reduction in EBITDA losses and strengthened its cash position through a new funding facility. Key clinical trials, including the Grass MATA MPL and VLP Peanut PROTECT, are progressing well, enhancing the company’s strategic outlook.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
